NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

ASMB

Assembly Biosciences Inc

Jun 23 • 04:00PM ET

17.10

Dollar change -0.29
Percentage change -1.67	%

Healthcare • Biotechnology • USA • NASD

Peers: GILD ABUS IONS ENTA MDGL NBIX VKTX ADAP OMER LXRX

| Held by: VTI VXF AVUV IWC AVSC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-6.24	Insider Own	47.35%	Shs Outstand	7.62M	Perf Week	1.48%
Market Cap	130.61M	Forward P/E	-	EPS next Y	-5.20	Insider Trans	35.24%	Shs Float	4.02M	Perf Month	25.83%
Enterprise Value	42.60M	PEG	-	EPS next Q	-1.67	Inst Own	12.65%	Short Float	0.35%	Perf Quarter	55.31%
Income	-39.92M	P/S	4.06	EPS this Y	23.97%	Inst Trans	-14.39%	Short Ratio	0.52	Perf Half Y	19.75%
Sales	32.15M	P/B	4.80	EPS next Y	-2.29%	ROA	-36.47%	Short Interest	0.01M	Perf YTD	8.37%
Book/sh	3.56	P/C	1.43	EPS next 5Y	13.45%	ROE	-133.65%	52W High	19.93 -14.20%	Perf Year	14.92%
Cash/sh	11.92	P/FCF	-	EPS past 3/5Y	42.93% 31.58%	ROIC	-134.75%	52W Low	7.75 120.65%	Perf 3Y	-24.60%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	65.83% 12.31%	Gross Margin	99.60%	Volatility	1.38% 3.08%	Perf 5Y	-93.46%
Dividend TTM	-	EV/Sales	1.32	EPS Y/Y TTM	42.41%	Oper. Margin	-138.81%	ATR (14)	0.85	Perf 10Y	-91.27%
Dividend Ex-Date	-	Quick Ratio	2.05	Sales Y/Y TTM	148.33%	Profit Margin	-124.15%	RSI (14)	67.33	Recom	1.67
Dividend Gr. 3/5Y	- -	Current Ratio	2.05	EPS Q/Q	29.04%	SMA20	7.33%	Beta	0.55	Target Price	30.00
Payout	-	Debt/Eq	0.11	Sales Q/Q	62.82%	SMA50	27.91%	Rel Volume	2.63	Prev Close	17.39
Employees	73	LT Debt/Eq	0.09	Earnings	May 08 AMC	SMA200	19.24%	Avg Volume	26.57K	Price	17.10
IPO	Dec 17, 2010	Option/Short	No / Yes	EPS/Sales Surpr.	26.88% 27.03%	Trades		Volume	69,889	Change	-1.67%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-25-25	Initiated	Guggenheim	Buy	$31
Sep-20-24	Upgrade	Jefferies	Hold → Buy	$2 → $35
Sep-13-21	Initiated	H.C. Wainwright	Neutral	$3.50
Sep-02-21	Downgrade	William Blair	Outperform → Mkt Perform
Mar-23-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Nov-06-20	Downgrade	Jefferies	Buy → Hold	$30 → $10
Oct-19-20	Initiated	Truist	Buy	$55
Oct-16-19	Initiated	Mizuho	Buy	$20
Nov-19-18	Initiated	Leerink Partners	Outperform	$45
Oct-08-18	Upgrade	B. Riley FBR	Neutral → Buy	$42
Aug-08-18	Initiated	Robert W. Baird	Outperform	$74
Apr-13-18	Downgrade	Chardan Capital Markets	Buy → Neutral	$35 → $50
Jan-05-18	Initiated	B. Riley FBR, Inc.	Neutral	$35
Nov-08-17	Initiated	Jefferies	Buy	$50
May-30-17	Initiated	Chardan Capital Markets	Buy	$35

Show Previous Ratings

May-27-25 04:05PM	Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference (GlobeNewswire)
May-08-25 05:40PM	Assembly Biosciences (ASMB) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -6.04%
04:36PM	Assembly Biosciences: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates (GlobeNewswire)
May-07-25 05:35PM	Amphastar Pharmaceuticals (AMPH) Tops Q1 Earnings Estimates (Zacks)
08:00AM	Loading…
08:00AM	New Preclinical Data for Assembly Biosciences' Oral Hepatitis D Virus Entry Inhibitor ABI-6250 and Next-Generation Hepatitis B Virus Capsid Assembly Modulator ABI-4334 Presented at the EASL Congress 2025 (GlobeNewswire)
May-05-25 09:47AM	Assembly Biosciences (ASMB) Soars 24.0%: Is Further Upside Left in the Stock? (Zacks)
Apr-29-25 05:35PM	BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +6.38%
Apr-09-25 02:00AM	Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress (GlobeNewswire)
Apr-08-25 09:35AM	Down -22.6% in 4 Weeks, Here's Why Assembly Biosciences (ASMB) Looks Ripe for a Turnaround (Zacks)
Mar-26-25 12:00PM	Assembly Biosciences (ASMB) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) -5.34%
Mar-20-25 04:53PM	Assembly Biosciences files for $250 mixed securities shelf (SeekingAlpha)
04:05PM	Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights (GlobeNewswire)
Mar-04-25 08:34PM	Is Assembly Biosciences, Inc. (ASMB) Among Stocks With At Least $20 Million In Insider Spending Recently? (Insider Monkey)
Feb-26-25 08:00AM	Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus (GlobeNewswire) +7.86%
08:00AM	Loading…
Feb-20-25 08:00AM	Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes (GlobeNewswire)
Dec-29-24 03:00AM	Gilead Buys $20.1 Million of Assembly Biosciences Stock (Barrons.com)
Dec-26-24 08:00AM	Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B (GlobeNewswire)
Dec-19-24 08:00AM	Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs (GlobeNewswire) +17.02%
Nov-07-24 06:19PM	Assembly Biosciences: Q3 Earnings Snapshot (Associated Press Finance) +5.11%
04:05PM	Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates (GlobeNewswire)
Sep-23-24 01:39PM	Assembly Biosciences' Investigational Herpes Treatment Shows Safety In Healthy Participants (UPDATED) (Benzinga) -16.31%
08:00AM	Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 (GlobeNewswire)
Sep-16-24 09:40AM	Is Assembly Biosciences (ASMB) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-08-24 05:22PM	Assembly Biosciences: Q2 Earnings Snapshot (Associated Press Finance) +6.02%
04:05PM	Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent Updates (GlobeNewswire)
Jul-15-24 08:00AM	Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop (GlobeNewswire)
Jun-18-24 08:00AM	Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 for the Treatment of Chronic Hepatitis B Virus Infection (GlobeNewswire)
Jun-17-24 08:00AM	Assembly Biosciences Announces $12.6 Million in Equity Financings (GlobeNewswire)
Jun-10-24 08:00AM	Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366 (GlobeNewswire) +6.51%
08:00AM	Loading…
Jun-05-24 08:00AM	Assembly Biosciences Presents New Data Highlighting Hepatitis D Virus Entry Inhibitor ABI-6250 at the EASL Congress 2024 (GlobeNewswire)
May-22-24 08:00AM	Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress 2024 (GlobeNewswire)
May-13-24 08:53AM	ASMB Stock Earnings: Assembly Biosciences Beats EPS for Q1 2024 (InvestorPlace)
May-09-24 05:04AM	Assembly Biosciences: Q1 Earnings Snapshot (Associated Press Finance)
May-08-24 04:05PM	Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights (GlobeNewswire)
Mar-28-24 10:53PM	ASMB Stock Earnings: Assembly Biosciences Beats EPS for Q4 2023 (InvestorPlace)
04:05PM	Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights (GlobeNewswire)
Mar-25-24 12:52PM	ASMB Stock Earnings: Assembly Biosciences Misses EPS for Q2 2023 (InvestorPlace)
Feb-08-24 08:00AM	Assembly Biosciences Announces Effective Date of Reverse Stock Split (GlobeNewswire)
Jan-04-24 08:00AM	Assembly Biosciences Provides Anticipated Development Milestones for 2024 (GlobeNewswire)
Nov-10-23 04:05PM	Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.11%
08:00AM	Assembly Biosciences Presents New Data Highlighting Viral Hepatitis Portfolio at AASLD The Liver Meeting (GlobeNewswire)
Nov-08-23 05:08PM	Assembly Biosciences: Q3 Earnings Snapshot (Associated Press Finance) -12.48%
04:05PM	Assembly Biosciences Reports Third Quarter 2023 Financial Results and Recent Updates (GlobeNewswire)
08:00AM	Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer (GlobeNewswire)
Oct-17-23 10:59AM	Why Is Assembly Biosciences (ASMB) Stock Up 92% Today? (InvestorPlace) +72.18%
07:00AM	Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases (Business Wire)
Oct-11-23 08:00AM	Assembly Biosciences to Present New Data at AASLD The Liver Meeting (GlobeNewswire)
Oct-02-23 08:00AM	Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor (GlobeNewswire)
Sep-19-23 04:05PM	Assembly Biosciences to Highlight Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting (GlobeNewswire) -5.72%
Aug-09-23 06:11PM	Assembly Biosciences: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Assembly Biosciences Reports Second Quarter 2023 Financial Results and Recent Updates (GlobeNewswire)
Jul-17-23 08:00AM	Assembly Biosciences Presents New Data Highlighting Herpes Simplex Virus Development Candidate ABI-5366 at the 47th Annual International Herpesvirus Workshop (GlobeNewswire)
Jun-21-23 08:00AM	Assembly Biosciences Presents New Data Highlighting Entry Inhibitor and Core Inhibitor Programs at EASLs International Liver Congress 2023 (GlobeNewswire)
Jun-07-23 08:00AM	Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL International Liver Congress 2023 (GlobeNewswire)
May-23-23 04:05PM	Assembly Biosciences to Present During the 2023 Jefferies Healthcare Conference (GlobeNewswire)
May-04-23 06:28PM	Assembly Biosciences: Q1 Earnings Snapshot (AP Finance)
04:05PM	Assembly Biosciences Reports First Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire)
Apr-18-23 08:00AM	Assembly Biosciences Announces Additional Promising Data from Phase 1a Clinical Trial Evaluating Highly Potent Next-Generation Core Inhibitor Candidate ABI-4334 and Provides Pipeline Update (GlobeNewswire)
Mar-30-23 10:04AM	Companies Like Assembly Biosciences (NASDAQ:ASMB) Could Be Quite Risky (Simply Wall St.) -10.11%
Mar-22-23 04:05PM	Assembly Biosciences Provides Update on its Core Inhibitor Pipeline, Reports Fourth Quarter and Year End 2022 Financial Results and Recent Highlights (GlobeNewswire) -8.55%
Feb-15-23 08:00AM	Assembly Biosciences Nominates First Herpesvirus Development Candidate ABI-5366, a Long-Acting HSV-2 Helicase Inhibitor Targeting High-Recurrence Genital Herpes (GlobeNewswire)
Dec-19-22 03:19PM	Assembly Biosciences Shares Gain After Promising Early Cut Data From HBV Infection Programs (Benzinga) +14.53%
08:00AM	Assembly Biosciences Announces Promising Interim Results from Two Clinical Trials Evaluating Highly Potent Next-Generation Core Inhibitor Candidates ABI-H3733 and ABI-4334 (GlobeNewswire)
Nov-14-22 08:00AM	Assembly Biosciences Doses First Subject in Phase 1a Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of Investigational Next Generation Core Inhibitor ABI-4334 (GlobeNewswire) +8.21%
Nov-09-22 09:35AM	After Plunging 17% in 4 Weeks, Here's Why the Trend Might Reverse for Assembly Biosciences (ASMB) (Zacks)
Nov-08-22 04:05PM	Assembly Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights and Announces Upcoming Conference Participation (GlobeNewswire) -7.43%
Nov-04-22 08:00AM	Assembly Biosciences Presents New Data at AASLD The Liver Meeting® Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core Inhibitors in HBV (GlobeNewswire) -5.00%
Oct-24-22 08:00AM	Assembly Biosciences to Present Data in Four Poster Presentations at Upcoming AASLD The Liver Meeting® (GlobeNewswire)
Oct-21-22 09:36AM	Can Assembly Biosciences (NASDAQ:ASMB) Afford To Invest In Growth? (Simply Wall St.)
Oct-05-22 04:05PM	Assembly Bio Announces Retirement of John G. McHutchison, AO, MD as CEO and Appoints Current President and COO Jason A. Okazaki as Successor (GlobeNewswire)
Aug-24-22 08:00AM	Assembly Biosciences to Host Webcast on August 31, 2022, Introducing Two New Research Programs Targeting Recurrent HSV-2 Infection and Transplant-Associated Herpesvirus Diseases (GlobeNewswire)
Aug-09-22 04:05PM	Assembly Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights (GlobeNewswire)
Aug-04-22 12:00PM	Assembly Biosciences (ASMB) Upgraded to Strong Buy: Here's Why (Zacks)
10:00AM	Best Momentum Stocks to Buy for August 4th (Zacks)
06:27AM	New Strong Buy Stocks for August 4th (Zacks)
Jul-21-22 07:22AM	The past five years for Assembly Biosciences (NASDAQ:ASMB) investors has not been profitable (Simply Wall St.) +7.83%
06:26AM	Disappointing Data Forces Assembly Bio Stop Combo Trial For HBV Infection (Benzinga)
Jul-20-22 05:48PM	Peninsula biotech to cut 30 jobs as it shuts down one hepatitis B to focus on others (American City Business Journals)
04:05PM	Assembly Biosciences Announces Program Reprioritization and Organizational Update (GlobeNewswire)
Jun-22-22 08:00AM	Assembly Biosciences Presents New Data Highlighting Clinical Progress of Core Inhibitor Programs at EASLs International Liver Congress 2022 (GlobeNewswire)
07:00AM	7 Penny Stocks That Could Triple in 2022 (InvestorPlace)
Jun-21-22 08:00AM	Assembly Biosciences to Introduce New Small Molecule Liver-Focused Interferon- Receptor Agonist Research Program in Webcast on July 26, 2022 (GlobeNewswire)
Jun-08-22 08:00AM	Assembly Biosciences to Highlight Data from HBV Core Inhibitor Programs at EASLs International Liver Congress 2022 (GlobeNewswire)
07:58AM	What Type Of Shareholders Own The Most Number of Assembly Biosciences, Inc. (NASDAQ:ASMB) Shares? (Simply Wall St.)
Jun-06-22 08:00AM	Assembly Biosciences Initiates Phase 1b Clinical Trial Evaluating Next Generation Core Inhibitor ABI-H3733 for the Treatment of Chronic Hepatitis B Virus Infection (GlobeNewswire)
Jun-03-22 04:05PM	Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.13%
May-27-22 09:38AM	Billionaire Israel Englander Pulls the Trigger on These 2 Strong Buy Penny Stocks (TipRanks) +10.29%
May-25-22 11:06AM	Peninsula biotech breaks off hepatitis B deal after partner's drug falters (American City Business Journals)
May-12-22 04:05PM	Assembly Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights (GlobeNewswire) +7.41% +6.21%
Apr-01-22 05:00PM	Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-23-22 04:19PM	Here's Why Assembly Biosciences (NASDAQ:ASMB) Must Use Its Cash Wisely (Simply Wall St.)
Mar-21-22 08:00AM	Assembly Biosciences to Highlight New Research Program for HBV/HDV Entry Inhibition in Webcast on March 31, 2022 (GlobeNewswire) +12.29%
Mar-10-22 04:05PM	Assembly Biosciences Reports Fourth Quarter and Year End 2021 Financial Results and Recent Highlights (GlobeNewswire)
Feb-09-22 08:00AM	Assembly Biosciences to Present During the SVB Leerink 11th Annual Global Healthcare Conference (GlobeNewswire)
Jan-19-22 09:38PM	Marquette Asset Management, LLC Buys Vanguard Total Bond Market ETF, ARK Next Generation ... (GuruFocus.com)
Jan-07-22 05:00PM	Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-06-22 08:00AM	Assembly Biosciences Announces Presentation During the 2022 H.C. Wainwright BIOCONNECT Virtual Conference (GlobeNewswire)
Jan-04-22 08:00AM	Assembly Biosciences Outlines Anticipated 2022 Pipeline Development Milestones (GlobeNewswire)
Dec-07-21 10:00AM	Down 30.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Assembly Biosciences (ASMB) (Zacks) +6.42%

Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses on two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin and Derek A. Small on October 7, 2005 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
McHutchison John G	Director	Mar 31 '25	Sale	9.85	757	7,455	18,347	Apr 15 05:30 PM
Bjorkquist Jeanette M	Principal Accounting Officer	Mar 31 '25	Sale	9.85	180	1,773	4,617	Apr 01 04:05 PM
Okazaki Jason A	CEO and President	Mar 31 '25	Sale	9.85	355	3,496	14,757	Apr 01 04:05 PM
White Nicole S	Chief Manufacturing Officer	Mar 31 '25	Sale	9.85	197	1,940	11,674	Apr 01 04:05 PM
Houghton Michael	Director	Dec 30 '24	Buy	15.61	3,202	49,998	3,202	Dec 31 04:24 PM
GILEAD SCIENCES, INC.	10% Owner	Dec 19 '24	Buy	21.37	940,499	20,098,464	2,209,471	Dec 23 08:26 PM
Schornstein Alexander	10% Owner	Nov 22 '24	Buy	14.87	17,024	253,104	720,137	Nov 26 09:15 AM
Schornstein Alexander	10% Owner	Nov 25 '24	Buy	14.91	7,976	118,890	728,113	Nov 26 09:15 AM
White Nicole S	Chief Manufacturing Officer	Nov 18 '24	Sale	16.29	40	652	11,871	Nov 19 04:05 PM
Schornstein Alexander	10% Owner	Oct 08 '24	Buy	14.58	10,000	145,800	703,113	Oct 09 09:15 AM
White Nicole S	Chief Manufacturing Officer	Oct 03 '24	Sale	14.81	157	2,325	11,911	Oct 04 04:05 PM
Okazaki Jason A	CEO and President	Oct 03 '24	Sale	14.81	197	2,918	14,904	Oct 04 04:05 PM
White Nicole S	Chief Manufacturing Officer	Aug 02 '24	Sale	14.23	785	11,173	12,068	Aug 05 04:10 PM
Okazaki Jason A	CEO and President	Aug 02 '24	Sale	14.23	981	13,962	15,101	Aug 05 04:05 PM
Schornstein Alexander	10% Owner	Jul 03 '24	Buy	12.29	4,562	56,067	688,675	Jul 08 10:48 AM
Schornstein Alexander	10% Owner	Jul 05 '24	Buy	12.52	4,438	55,564	693,113	Jul 08 10:48 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ASMB

Assembly Biosciences Inc

Upgrade your FINVIZ experience